{"id":83622,"date":"2020-04-18T00:02:22","date_gmt":"2020-04-18T03:02:22","guid":{"rendered":"https:\/\/megalabs.global\/eng\/?p=83622"},"modified":"2020-04-23T18:45:52","modified_gmt":"2020-04-23T21:45:52","slug":"interferon-alfa-2b","status":"publish","type":"post","link":"https:\/\/megalabs.global\/eng\/interferon-alfa-2b\/","title":{"rendered":"Interfer\u00f3n alfa-2B"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”100″ gutter_size=”3″ shift_y=”0″ row_height_use_pixel=””][vc_column column_width_use_pixel=”yes” gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ medium_width=”0″ zoom_width=”0″ zoom_height=”0″ column_width_pixel=”800″][vc_column_text]El Interfer\u00f3n-alfa-2B es un antiviral indicado para el tratamiento de la hepatitis cr\u00f3nica C (CHC) en pacientes con enfermedad hep\u00e1tica compensada.
\nFue aprobado por la FDA en el a\u00f1o 2001. (2)<\/p>\n

Dosis y administraci\u00f3n propuestas para COVID-19(1)<\/strong>
\nAdultos<\/strong><\/em>
\nDosis: 250 microgramos administrados por v\u00eda subcut\u00e1nea cada 48 h durante 14 d\u00edas.<\/p>\n

Precauciones y advertencias (2)<\/strong>
\nSi se administra con ribavirina, las advertencias y precauciones para la ribavirina tambi\u00e9n se aplican a este r\u00e9gimen combinado. Los pacientes que exhiben las siguientes condiciones deben ser monitoreados de cerca y pueden requerir una reducci\u00f3n de la dosis o la interrupci\u00f3n de la terapia:
\n\u2022 Eventos neuropsiqui\u00e1tricos.
\n\u2022 Historia de enfermedad card\u00edaca significativa o inestable.
\n\u2022 Hipotiroidismo, hipertiroidismo, hiperglucemia, diabetes mellitus que no pueden tratarse eficaz-mente con medicamentos.
\n\u2022 Trastornos oftalmol\u00f3gicos nuevos o que empeoran.
\n\u2022 Eventos cerebrovasculares isqu\u00e9micos y hemorr\u00e1gicos.
\n\u2022 Disminuciones severas en el recuento de neutr\u00f3filos o plaquetas.
\n\u2022 Historia de trastornos autoinmunes.
\n\u2022 Pancreatitis y colitis y pancreatitis ulcerosa o hemorr\u00e1gica \/ isqu\u00e9mica.
\n\u2022 Infiltrados pulmonares o deterioro de la funci\u00f3n pulmonar.
\n\u2022 Puntaje de Child-Pugh mayor a 6 (clase B y C).
\n\u2022 Aumento de los niveles de creatinina en pacientes con insuficiencia renal.
\n\u2022 Reacciones graves de hipersensibilidad aguda y erupciones cut\u00e1neas.
\n\u2022 Trastornos dentales \/ periodontales informados con terapia combinada.
\n\u2022 P\u00e9rdida de peso e inhibici\u00f3n del crecimiento informada durante la terapia combinada en pacien-tes pedi\u00e1tricos.
\n\u2022 Inhibici\u00f3n del crecimiento a largo plazo (altura)
\n\u2022 Neuropat\u00eda perif\u00e9rica cuando se usa en combinaci\u00f3n con telbivudina.<\/p>\n

Eventos adversos (2)<\/strong>
\nFiebre, cefalea, hiperton\u00eda, miastenia, rash, n\u00e1usea, diarrea, linfopenia, leucopenia, reacci\u00f3n local, debilidad, artralgia, s\u00edndrome pseudogripal.
\nLos riesgos a destacar asociado a este medicamento son los des\u00f3rdenes pulmonares, los cuales incluyen infiltrados pulmonares, neumon\u00eda, disnea, bronquiolitis obliterante, neumonitis intersticial, hipertensi\u00f3n pulmonar, sarcoidosis e insuficiencia respiratoria.<\/p>\n

Estudios cl\u00ednicos con COVID-19<\/strong>
\n\u2022 Evaluation of Ganovo \uff08Danoprevir \uff09 Combined With Ritonavir in the Treatment of Novel Coronavirus Infection. (3)[\/vc_column_text][vc_single_image media=”83628″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”715″][vc_column_text]\u2022 Experimental Trial of rhIFN\u03b1 Nasal Drops to Prevent 2019-nCOV in Medical Staff. (4)[\/vc_column_text][vc_single_image media=”83629″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”714″][vc_column_text]\u2022 Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treat-ment\/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19). (5)[\/vc_column_text][vc_single_image media=”83630″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”713″][vc_column_text]\u2022 A Prospective\/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia. (6)[\/vc_column_text][vc_single_image media=”83631″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”713″][vc_column_text]\u2022 Efficacy and Safety of INF-\u03b12\u03b2 in the Treatment of Novel Coronavirus Patients\u00a0 (7)[\/vc_column_text][vc_single_image media=”83632″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”708″][vc_column_text]\u2022 Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe). (8)[\/vc_column_text][vc_single_image media=”83633″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”712″][vc_column_text]Link a informaci\u00f3n del producto de FDA:
\nwww.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103949s5313lbl.pdf<\/a>.<\/p>\n

(1) Tratamientos disponibles para el manejo de la infecci\u00f3n respiratoria por SARS-CoV-2. AEMPS2020.
\nAvailable from: https:\/\/www.aemps.gob.es\/la-aemps\/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119\/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2\/<\/a>.<\/p>\n

(2) Inserto Pegintron Food and Drug Administration2019.
\nAvailable from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103949s5313lbl.pdf<\/a>.<\/p>\n

(3) Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Corona-virus Infection 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04291729<\/a>.<\/p>\n

(4) Experimental Trial of rhIFN\u03b1 Nasal Drops to Prevent 2019-nCOV in Medical Staff 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320238<\/a>.<\/p>\n

(5) Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment\/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneu-monia (COVID-19) 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273763<\/a>.<\/p>\n

(6) A Prospective\/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia. 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04254874<\/a>.<\/p>\n

(7) Efficacy and Safety of INF-\u03b12\u03b2 in the Treatment of Novel Coronavirus Patients.(2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04293887<\/a>.<\/p>\n

(8) Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04295551<\/a>.[\/vc_column_text][vc_empty_space empty_h=”3″][vc_row_inner row_inner_height_percent=”0″ overlay_alpha=”50″ gutter_size=”3″ border_color=”color-877404″ border_style=”solid” shift_y=”0″ z_index=”0″ css=”.vc_custom_1572995729128{border-top-width: 1px !important;border-bottom-width: 1px !important;padding-top: 18px !important;padding-bottom: 18px !important;}” el_class=”descarga-pdf” limit_content=””][vc_column_inner width=”1\/1″][vc_icon position=”left” icon_image=”82110″ icon_color=”color-877404″ media_size=”42″ text_font=”font-195522″ text_weight=”700″ linked_title=”yes” title=”Descargar Documento” link=”url:%2Fwp-content%2Fuploads%2F2020%2F04%2FConexi%C3%B3n_Interferon-alfa.pdf|title:Conexi%C3%B3n_Interferon%20alfa|target:%20_blank|”]Conexi\u00f3n_Interferon alfa[\/vc_icon][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Inyectable<\/p>\n","protected":false},"author":1,"featured_media":80575,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[94],"tags":[],"class_list":["post-83622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farmacos"],"_links":{"self":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/83622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/comments?post=83622"}],"version-history":[{"count":0,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/83622\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media\/80575"}],"wp:attachment":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media?parent=83622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/categories?post=83622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/tags?post=83622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}